Zacks: Innophos Holdings, Inc. (IPHS) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Innophos Holdings, Inc. (NASDAQ:IPHS) have been assigned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.

Zacks has also assigned Innophos an industry rank of 210 out of 256 based on the ratings given to related companies.

Several equities analysts recently issued reports on the stock. BidaskClub upgraded shares of Innophos from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Zacks Investment Research upgraded shares of Innophos from a “strong sell” rating to a “hold” rating in a research note on Friday, January 4th. Finally, ValuEngine cut shares of Innophos from a “hold” rating to a “sell” rating in a research note on Friday, October 12th.

A number of large investors have recently bought and sold shares of IPHS. Confluence Investment Management LLC grew its holdings in shares of Innophos by 6.4% during the fourth quarter. Confluence Investment Management LLC now owns 119,672 shares of the specialty chemicals company’s stock worth $2,935,000 after buying an additional 7,248 shares in the last quarter. Teachers Advisors LLC grew its holdings in shares of Innophos by 4.3% during the third quarter. Teachers Advisors LLC now owns 37,859 shares of the specialty chemicals company’s stock worth $1,681,000 after buying an additional 1,550 shares in the last quarter. Vanguard Group Inc grew its holdings in shares of Innophos by 2.0% during the third quarter. Vanguard Group Inc now owns 2,065,439 shares of the specialty chemicals company’s stock worth $91,705,000 after buying an additional 41,101 shares in the last quarter. LaFleur & Godfrey LLC purchased a new stake in shares of Innophos during the third quarter worth $708,000. Finally, Vanguard Group Inc. grew its holdings in shares of Innophos by 2.0% during the third quarter. Vanguard Group Inc. now owns 2,065,439 shares of the specialty chemicals company’s stock worth $91,705,000 after buying an additional 41,101 shares in the last quarter. Institutional investors own 94.20% of the company’s stock.

NASDAQ IPHS traded up $0.43 on Wednesday, hitting $27.02. 9,242 shares of the company’s stock traded hands, compared to its average volume of 123,802. The company has a current ratio of 2.79, a quick ratio of 1.36 and a debt-to-equity ratio of 1.01. Innophos has a 1-year low of $22.57 and a 1-year high of $50.40. The stock has a market cap of $504.54 million, a price-to-earnings ratio of 10.81 and a beta of 1.22.

Innophos (NASDAQ:IPHS) last posted its earnings results on Thursday, November 1st. The specialty chemicals company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by ($0.01). Innophos had a net margin of 2.49% and a return on equity of 13.30%. The firm had revenue of $196.93 million during the quarter, compared to analyst estimates of $197.20 million. During the same quarter in the prior year, the firm earned $0.78 earnings per share. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. Analysts forecast that Innophos will post 2.25 EPS for the current year.

About Innophos

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

Further Reading: How Do You Calculate Return on Investment (ROI)?

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit